Purpose The current standard-of-care for front-line therapy for acute myeloid leukaemia
(AML) is a combination of an anthracycline with cytarabine resulting in significant short-term …

Learning Objectives After completing this course, the reader will be able to: Identify specific
favorable and high-risk factors in pediatric AML. Discuss the rationale and indications for the …

Victor M. Aquino, MD~ cute myelogenous leukemia (AML) is charac-terized by the
overproduction of immature myeloid cells in the bone marrow, which leads to bone marrow …

The objectives of this review were to discuss standard and investigational treatment
strategies for adolescent and young adult with acute myeloid leukemia, excluding acute …

The prognosis of paediatric acute myeloid leukaemia (AML) has improved significantly over
the recent decades, but still about one‐third of patients relapse. These patients have a …

Purpose Karyotype is an independent indicator of prognosis in acute myeloid leukemia
(AML) that is widely applied to risk-adapted therapy. Because AML is rare in children, the …

Pediatric acute myeloid leukemia is a rare and heterogeneous disease in relation to
morphology, immunophenotyping, germline and somatic cytogenetic and genetic …

Data on childhood acute myeloid leukemia (AML) in developing countries are limited.
Herein we report the outcome of childhood AML treated with modified NPCLC-AML97 in our …

Abstract Between May 1988 and June 2000, 698 children were treated in the Medical
Research Council acute myeloid leukemia 10 and 12 trials. The presenting features and …

Acute myeloid leukemia (AML) is a heterogeneous clonal disorder characterized by
immature myeloid cell proliferation and bone marrow failure. Cytogenetics and mutation …